Eleven children who were legally blind at birth all gained visual acuity after receiving MeiraGTx's investigational gene ...

The R&D head is looking for "clever science," which Friberg said is readily apparent in BioMarin’s recent research pact with ...

Roche has put forward a new approach to genetic analysis, which it describes as sequencing-by-expansion—a proprietary method ...

As part of an agreement announced two weeks ago, eye-disease-focused Acelyrin was due to be absorbed into immune-mediated ...

Celia Witten, M.D., Ph.D., is no longer deputy director of the FDA’s Center for Biologics Evaluation and Research (CBER), joining the long list of health agency leaders who have departed since ...

“Partnering with Genesis Therapeutics presents a unique opportunity to leverage their AI technologies to accelerate the ...

Clinical-stage drug development offers big rewards—and big risks. | This week on "The Top Line," we dive into several of the ...

On Jan. 2, Hookipa inked a non-binding agreement that would have created a merged company with Poolbeg via an all-stock ...

Illumina is raising the curtain on its upcoming entry into spatial transcriptomics, with tech designed to help researchers ...

The NIH has lost two distinguished leaders as mass layoffs directed by the Trump administration hit federal health agencies.

The Trump administration is exploiting an administrative loophole to keep federal research funding frozen, despite a federal judge ordering for a halt to the action, according to Nature.

While the FDA’s diversity guidance for clinical trials has been temporarily restored, the page it is housed on now carries a ...